An expert panel made up of two advisory committees has voted overwhelmingly
for the FDA to impose strict new limitations on the multi-billion dollar
testosterone drug industry. It was recommended that the labels for such
medications be updated to prevent them from being prescribed to men who
only have low testosterone due to aging, as opposed to hypogonadism, a
disorder where a man's body is incapable of producing testosterone
and for which the use of low-t drugs is approved by the FDA.
The recommendation follows the first day of a two-day meeting (the second
of which continues today), the need for which was prompted by studies
finding that testosterone replacement drugs cause a myriad of health problems,
and fueled by ongoing litigation brought against testosterone drug manufacturers
for that reason. Morelli Law Firm is at the forefront of the litigation,
having filed the first cases in the country alleging health problems including
blood clots, heart attacks and strokes.
Click here for the full article, and stay tuned for more.